Asset Details
Do you wish to reserve the book?
Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience
Do you wish to request the book?
Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience
2017
Overview
Background
Few studies have been conducted on the long-term prognosis of patients with amyloid light chain (AL) and amyloid A (AA) renal amyloidosis in the same cohort.
Methods
We retrospectively examined 68 patients with biopsy-proven renal amyloidosis (38 AL and 30 AA). Clinicopathological findings at the diagnosis and follow-up data were evaluated in each patient. We analyzed the relationship between clinicopathological parameters and survival data.
Results
Significant differences were observed in several clinicopathological features, such as proteinuria levels, between the AL and AA groups. Among all patients, 84.2 % of the AL group and 93.3 % of the AA group received treatments for the underlying diseases of amyloidosis. During the follow-up period (median 18 months in AL and 61 months in AA), 36.8 % of the AL group and 36.7 % of the AA group developed end-stage renal failure requiring dialysis, while 71.1 % of the AL group and 56.7 % of the AA group died. Patient and renal survivals were significantly longer in the AA group than in the AL group. eGFR of >60 mL/min/1.73 m
2
at biopsy and an early histological stage of glomerular amyloid deposition were identified as low-risk factors. A multivariate analysis showed that cardiac amyloidosis and steroid therapy significantly influenced patient and renal survivals.
Conclusions
Our results showed that heart involvement was the major predictor of poor outcomes in renal amyloidosis, and that the prognosis of AA renal amyloidosis was markedly better than that in previously reported cohorts. Therapeutic advances in inflammatory diseases are expected to improve the prognosis of AA amyloidosis.
Publisher
Springer Science and Business Media LLC,Springer Japan,Springer Nature B.V
Subject
/ Aged
/ Biopsy
/ Cardiomyopathies - immunology
/ Cardiomyopathies - mortality
/ Female
/ Fibrosis
/ Humans
/ Immunoglobulin Light Chains - immunology
/ Japan
/ Kidney
/ Kidney Diseases - immunology
/ Kidney Failure, Chronic - immunology
/ Kidney Failure, Chronic - mortality
/ Kidney Failure, Chronic - therapy
/ Male
/ Medicine
/ Serum Amyloid A Protein - immunology
/ Urology
